首页 正文

Measuring the Impact of tolvaptan-induced polyuria on quality of life in patients with autosomal dominant polycystic kidney disease

{{output}}
Introduction: Tolvaptan, a vasopressin V2 receptor antagonist (V2RA), is the only proven renoprotective therapy for patients with autosomal dominant polycystic kidney disease (ADPKD), but aquaretic side-effects limit its tolerabi... ...